This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Offing for Cisco Systems' (CSCO) Q4 Earnings?
by Zacks Equity Research
Cisco (CSCO) is benefiting from its expanding footprint in the rapidly growing security market. Also, partnerships and synergies from acquisitions will boost the company's revenue base.
Myriad Genetics' Elevate 2020 Plan Holds Promise Amid Issues
by Zacks Equity Research
Myriad Genetics (MYGN) unveils an 'Elevate 2020' program that aims to generate $50 million in incremental operating income by fiscal 2020.
Why Is Myriad (MYGN) Down 6.4% Since Last Earnings Report?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics Divests NAMIC Portfolio to Medline Industries
by Zacks Equity Research
The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.
Myriad Genetics Announces Study Results Of myRisk Cancer Test
by Zacks Equity Research
The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.
Myriad Genetics' (MYGN) POLO Study Shows Positive Results
by Zacks Equity Research
Myriad Genetics' (MYGN) collaboration with AstraZeneca garners several regulatory go-aheads for BRACAnalysis CDx test.
Why Should You Hold on to Myriad Genetics (MYGN) Stock?
by Zacks Equity Research
Investor confidence is still high on growth prospects of Myriad Genetics (MYGN).
Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up
by Zacks Equity Research
Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.
Myriad Genetics (MYGN) Beats Q3 Earnings Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 4.55% and -0.81%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
The global medical device space takes significant strides in terms of research and development (R&D) and regulatory progress in the first quarter.
Myriad Genetics Expands CDx Tie Up With AstraZeneca & Merck
by Zacks Equity Research
The expanded partnership will help Myriad Genetics (MYGN) boost top-line contributions in the near term.
Myriad Genetics New Study Data to Lift Prenatal Tests' Uptake
by Zacks Equity Research
The recent development will help Myriad Genetics (MYGN) to boost top-line contributions from prenatal tests.
Myriad Genetics Gains on Innovation, New Reimbursements
by Zacks Equity Research
Myriad Genetics (MYGN) aims at raising revenues by commercializing its product suite that includes Vectra DA, Prolaris, myPath Melanoma, Companion Diagnostics, EndoPredict and myPlan Lung Cancer Test.
Myriad's myPath Melanoma Test Awarded Medicare Coverage
by Zacks Equity Research
The latest nod from Medicare Coverage for Myriad's (MYGN) myPath Melanoma test is likely to boost top-line results in the near term.
Why Is Myriad (MYGN) Down 0.5% Since Last Earnings Report?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics (MYGN) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) Q2 performance by Hereditary Cancer testing is encouraging while GeneSight test revenues disappoint.
Myriad Genetics (MYGN) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of -7.32% and -0.76%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?
by Zacks Equity Research
Myriad (MYGN) likely to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.
Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A Bullish 2019 is Not a Con
by John Blank
It's Sounds Like a Marketing Ploy. It's Not.
Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
On the success of the Elevate 2020 program, along with augmenting reimbursements for tests, Myriad Genetics (MYGN) seems to be well-positioned to deliver strong financial results in fiscal 2019.
MYGN vs. SWTUY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MYGN vs. SWTUY: Which Stock Is the Better Value Option?
Has Myriad Genetics (MYGN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MYGN) Outperforming Other Medical Stocks This Year?
Epizyme to File NDA for Tazemetostat in Follicular Lymphoma
by Zacks Equity Research
Epizyme (EPZM) announces that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma.